A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer

Chong Kun Im, Hei Cheul Jeung, SunYoung Rha, Nae Choon Yoo, Sung Hoon Noh, Jae Kyung Roh, Hyuncheol Chung

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: The aim of this study was to investigate the efficacy and safety of the combination chemotherapy of paclitaxel, infusional 5-fluorouracil (5-FU) and leucovorin (FLT regimen) in advanced gastric cancer. The primary end point was the time to progression (TTP). Methods: Patients with evaluable disease with or without measurable lesions received 175 mg/m2 paclitaxel on day 1 followed by 20 mg/m2 leucovorin and 24-h infusion of 5-FU 1,000 mg/m2 (day 1-3) repeated every 3 weeks. Results: Sixty patients were enrolled. The median TTP and overall survival duration were 13 and 60 weeks, respectively. One-year survival rate was 53.3%. Of the 50 patients with measurable lesion, the overall response rate was 31.7%. The most common grade 3-4 adverse event was neutropenia (61.7%). Conclusion: The FLT regimen showed an efficacy comparable to other regimens of cisplatin or anthracycline combinations with the advantage of remarkably low non-hematological toxicity. These data about the efficacy of this regimen need confirmation in a phase III trial.

Original languageEnglish
Pages (from-to)315-321
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume61
Issue number2
DOIs
Publication statusPublished - 2008 Feb 1

Fingerprint

Leucovorin
Paclitaxel
Fluorouracil
Stomach Neoplasms
Chemotherapy
Anthracyclines
Cisplatin
Toxicity
Combination Drug Therapy
Neutropenia
Survival Rate
Safety
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Im, Chong Kun ; Jeung, Hei Cheul ; Rha, SunYoung ; Yoo, Nae Choon ; Noh, Sung Hoon ; Roh, Jae Kyung ; Chung, Hyuncheol. / A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. In: Cancer Chemotherapy and Pharmacology. 2008 ; Vol. 61, No. 2. pp. 315-321.
@article{df762e889e9741fd9a32c1fd22cceb1a,
title = "A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer",
abstract = "Purpose: The aim of this study was to investigate the efficacy and safety of the combination chemotherapy of paclitaxel, infusional 5-fluorouracil (5-FU) and leucovorin (FLT regimen) in advanced gastric cancer. The primary end point was the time to progression (TTP). Methods: Patients with evaluable disease with or without measurable lesions received 175 mg/m2 paclitaxel on day 1 followed by 20 mg/m2 leucovorin and 24-h infusion of 5-FU 1,000 mg/m2 (day 1-3) repeated every 3 weeks. Results: Sixty patients were enrolled. The median TTP and overall survival duration were 13 and 60 weeks, respectively. One-year survival rate was 53.3{\%}. Of the 50 patients with measurable lesion, the overall response rate was 31.7{\%}. The most common grade 3-4 adverse event was neutropenia (61.7{\%}). Conclusion: The FLT regimen showed an efficacy comparable to other regimens of cisplatin or anthracycline combinations with the advantage of remarkably low non-hematological toxicity. These data about the efficacy of this regimen need confirmation in a phase III trial.",
author = "Im, {Chong Kun} and Jeung, {Hei Cheul} and SunYoung Rha and Yoo, {Nae Choon} and Noh, {Sung Hoon} and Roh, {Jae Kyung} and Hyuncheol Chung",
year = "2008",
month = "2",
day = "1",
doi = "10.1007/s00280-007-0508-6",
language = "English",
volume = "61",
pages = "315--321",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. / Im, Chong Kun; Jeung, Hei Cheul; Rha, SunYoung; Yoo, Nae Choon; Noh, Sung Hoon; Roh, Jae Kyung; Chung, Hyuncheol.

In: Cancer Chemotherapy and Pharmacology, Vol. 61, No. 2, 01.02.2008, p. 315-321.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer

AU - Im, Chong Kun

AU - Jeung, Hei Cheul

AU - Rha, SunYoung

AU - Yoo, Nae Choon

AU - Noh, Sung Hoon

AU - Roh, Jae Kyung

AU - Chung, Hyuncheol

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Purpose: The aim of this study was to investigate the efficacy and safety of the combination chemotherapy of paclitaxel, infusional 5-fluorouracil (5-FU) and leucovorin (FLT regimen) in advanced gastric cancer. The primary end point was the time to progression (TTP). Methods: Patients with evaluable disease with or without measurable lesions received 175 mg/m2 paclitaxel on day 1 followed by 20 mg/m2 leucovorin and 24-h infusion of 5-FU 1,000 mg/m2 (day 1-3) repeated every 3 weeks. Results: Sixty patients were enrolled. The median TTP and overall survival duration were 13 and 60 weeks, respectively. One-year survival rate was 53.3%. Of the 50 patients with measurable lesion, the overall response rate was 31.7%. The most common grade 3-4 adverse event was neutropenia (61.7%). Conclusion: The FLT regimen showed an efficacy comparable to other regimens of cisplatin or anthracycline combinations with the advantage of remarkably low non-hematological toxicity. These data about the efficacy of this regimen need confirmation in a phase III trial.

AB - Purpose: The aim of this study was to investigate the efficacy and safety of the combination chemotherapy of paclitaxel, infusional 5-fluorouracil (5-FU) and leucovorin (FLT regimen) in advanced gastric cancer. The primary end point was the time to progression (TTP). Methods: Patients with evaluable disease with or without measurable lesions received 175 mg/m2 paclitaxel on day 1 followed by 20 mg/m2 leucovorin and 24-h infusion of 5-FU 1,000 mg/m2 (day 1-3) repeated every 3 weeks. Results: Sixty patients were enrolled. The median TTP and overall survival duration were 13 and 60 weeks, respectively. One-year survival rate was 53.3%. Of the 50 patients with measurable lesion, the overall response rate was 31.7%. The most common grade 3-4 adverse event was neutropenia (61.7%). Conclusion: The FLT regimen showed an efficacy comparable to other regimens of cisplatin or anthracycline combinations with the advantage of remarkably low non-hematological toxicity. These data about the efficacy of this regimen need confirmation in a phase III trial.

UR - http://www.scopus.com/inward/record.url?scp=36348949070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36348949070&partnerID=8YFLogxK

U2 - 10.1007/s00280-007-0508-6

DO - 10.1007/s00280-007-0508-6

M3 - Article

VL - 61

SP - 315

EP - 321

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -